Family Medicine
Opinion: Despite Omicron arriving, keeping schools open as safely as possible should be the goal.
27 Jan, 2022 | 09:58h | UTC
AAP Report: Some alternative peripartum, neonatal practices carry disease risks.
27 Jan, 2022 | 09:41h | UTCNews Release: Some alternative peripartum, neonatal practices carry disease risks: AAP report – American Academy of Pediatrics
Report: Risks of Infectious Diseases in Newborns Exposed to Alternative Perinatal Practices – Pediatrics
Commentary: Risks Discussed for Alternative Peripartum, Neonatal Practices – HealthDay
Perspective: From vaginal laser treatment to spa breaks – it’s the great menopause gold rush.
27 Jan, 2022 | 09:36h | UTCFrom vaginal laser treatment to spa breaks – it’s the great menopause gold rush – The Guardian
Review | Immune-checkpoint inhibitors: long-term implications of toxicity.
27 Jan, 2022 | 09:39h | UTCImmune-checkpoint inhibitors: long-term implications of toxicity – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
New Review by Douglas Johnson, Caroline Nebhan, Javid Moslehi (@CardioOncology) & Justin Balko now live online: 'Immune-checkpoint inhibitors: long-term implications of toxicity' https://t.co/7ymExYiqEY #ImmunoOnc #medonc pic.twitter.com/m6m92mZwOZ
— NatureRevClinOncol (@NatRevClinOncol) January 26, 2022
ESC Position Statement: Cardiovascular effects of doping substances, commonly prescribed medications, and ergogenic aids in relation to sports.
27 Jan, 2022 | 09:43h | UTCNews Release: Athletes warned against potential dangers of natural supplements – European Society of Cardiology
Systematic Review: Mediators between physical activity and academic achievement.
27 Jan, 2022 | 09:28h | UTC
RCT: In children with relapsing steroid-sensitive nephrotic syndrome with acute respiratory tract infection, a daily low dose of prednisolone did not reduce the risk of relapse.
27 Jan, 2022 | 09:32h | UTCCommentary: PREDNOS 2: Prednisolone Doesn’t Lower Relapse Risks in Kids with Nephrotic Syndrome – Physician’s Weekly
Commentary on Twitter
In a large non-selected sample of children (365) with relapsing steroid sensitive nephrotic syndrome, the PREDNOS 2 RCT has shown that low dose prednisolone given for 6 days at the start of an URTI does not reduce the risk of relapse https://t.co/9271PHQh0r
— JAMA Pediatrics (@JAMAPediatrics) December 20, 2021
Iron deficiency anemia: pathophysiology, assessment, practical management.
27 Jan, 2022 | 09:30h | UTC
Short-term glucocorticoid-related side effects and adverse reactions: a narrative review and practical approach.
27 Jan, 2022 | 09:18h | UTC
Cohort study: Among patients who survived ICU treatment for COVID-19, 75% still reported physical, mental, or cognitive symptoms after 1 year.
26 Jan, 2022 | 02:28h | UTCCommentaries:
75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP
Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical
USPSTF Recommendation Statement: Still not enough evidence to recommend atrial fibrillation screening.
26 Jan, 2022 | 02:08h | UTCAuthor Interview: USPSTF Recommendation: Screening for Atrial Fibrillation – JAMA
Editorials:
Screening for Atrial Fibrillation—More Data Still Needed – JAMA
Screening for Atrial Fibrillation—New Devices, Same Challenges – JAMA Internal Medicine
Screening for Atrial Fibrillation—Refining the Target – JAMA Network Open
JAMA Patient Page: Screening for Atrial Fibrillation
Commentary: USPSTF: Data Around Screening for AF in Asymptomatic Adults Still Lacking – TCTMD
[Preprint] High prevalence of olfactory disorders 18 months after contracting COVID-19.
26 Jan, 2022 | 02:11h | UTCHigh prevalence of olfactory disorders 18 months after contracting COVID-19 – medRxiv
Commentaries:
Half of first-wave Covid cases may have lasting harm to sense of smell – The Guardian
Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection – News Medical
RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.
26 Jan, 2022 | 01:58h | UTC
Commentary on Twitter
In this 2-year study, data showed that electronic directly observed therapy (eDOT) was as effective as traditional in-person DOT for ensuring high adherence to treatment of tuberculosis disease. @CDC_TB @nycHealthy @ColumbiaMed https://t.co/yTrU1JRuwn pic.twitter.com/QXthE4d266
— JAMA Network Open (@JAMANetworkOpen) January 20, 2022
Fever of unknown origin and incidence of cancer: a population-based cohort study using nationwide Danish registries showed that cancer risk in one year was 1.2%.
26 Jan, 2022 | 01:36h | UTCFever of unknown origin and incidence of cancer – Clinical Infectious Diseases (link to abstract – $ for full-text)
Systematic Review: Oral antihistamine‐decongestant‐analgesic combinations for the common cold.
26 Jan, 2022 | 01:31h | UTCOral antihistamine‐decongestant‐analgesic combinations for the common cold – Cochrane Library
Commentary: Oral antihistamine-decongestant-analgesic combinations for the common cold – Cochrane Library
Systematic Review: Short intravenous antibiotic courses for urinary infections in young infants.
26 Jan, 2022 | 01:24h | UTCShort Intravenous Antibiotic Courses for Urinary Infections in Young Infants: A Systematic Review – Pediatrics (link to abstract – $ for full-text)
Supplement: Irritable bowel syndrome and related conditions.
26 Jan, 2022 | 01:21h | UTCHomepage: IBS and Related Conditions – Alimentary Pharmacology and Therapeutics
Review article: epidemiology of IBS and other bowel disorders of gut–brain interaction (DGBI)
Review article: Physical and psychological comorbidities associated with irritable bowel syndrome
Review article: Diagnosis and investigation of irritable bowel syndrome
Review article: current and future treatment approaches for IBS with constipation
Review article: current and future treatment approaches for pain in IBS
ACP living, rapid review: risk for reinfection after SARS-CoV-2.
25 Jan, 2022 | 09:47h | UTC
Commentary on Twitter
Risk for Reinfection After #SARSCoV2: previous infection reduced risk for reinfection by 87% (95% CI, 84% to 90%). Protection remained above 80% for at least 7 months, but no study followed patients after the emergence of the Delta or #Omicron variant. https://t.co/eruEf1w8Vo
— Prof. Nick Talley (@Prof_NickTalley) January 25, 2022
WHO drops opposition to boosters – recommends third Pfizer jab for adults & two vaccines for children ages 5 & up.
25 Jan, 2022 | 09:45h | UTCRelated:
WHO updated roadmap for prioritizing uses of COVID-19 vaccines.
WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.
A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.
25 Jan, 2022 | 09:43h | UTCNews release: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians
Related:
[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.
Heart-inflammation risk from Pfizer COVID vaccine is very low.
ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question in children.
25 Jan, 2022 | 09:33h | UTCSee complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Guidelines on Screen Time and Digital Wellness in Infants, Children and Adolescents – “children below 2 years age should not be exposed to any type of screen, whereas exposure should be limited to a maximum of one hour of supervised screen time per day for children 24-59 months age, and less than two hours per day for children 5-10 years age”.
25 Jan, 2022 | 09:30h | UTCRelated Guideline: Media and Young Minds – American Academy of Pediatrics
Review: Diagnosis and management of functional neurological disorder.
25 Jan, 2022 | 09:22h | UTCDiagnosis and management of functional neurological disorder – The BMJ
RCT: Single-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone for the treatment of gonorrhea.
25 Jan, 2022 | 09:20h | UTCEfficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
New from @TheLancetInfDis Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial by @henryjdevries and colleagues https://t.co/K2fw5ORNlm pic.twitter.com/d8wz1Vc41Q
— The Lancet HIV (@TheLancetHIV) January 24, 2022
Podcast: Erectile dysfunction pearls.
25 Jan, 2022 | 09:16h | UTC#317 Erectile Dysfunction – The Curbsiders